首页> 美国卫生研究院文献>BMC Cancer >No influence of the polymorphisms CYP2C19 and CYP2D6 on the efficacy of cyclophosphamide thalidomide and bortezomib in patients with Multiple Myeloma

【2h】

No influence of the polymorphisms CYP2C19 and CYP2D6 on the efficacy of cyclophosphamide thalidomide and bortezomib in patients with Multiple Myeloma

机译：CYP2C19和CYP2D6多态性对多发性骨髓瘤患者环磷酰胺沙利度胺和硼替佐米的疗效无影响

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

BackgroundThe response to treatment varies among patients with multiple myeloma and markers for prediction of treatment outcome are highly needed. Bioactivation of cyclophosphamide and thalidomide, and biodegradation of bortezomib, is dependent on cytochrome P450 metabolism. We explored the potential influence of different polymorphisms in the CYP enzymes on the outcome of treatment.

机译：背景多发性骨髓瘤患者对治疗的反应各不相同，因此非常需要用于预测治疗结果的标志物。环磷酰胺和沙利度胺的生物活化以及硼替佐米的生物降解取决于细胞色素P450的代谢。我们探讨了CYP酶中不同多态性对治疗结果的潜在影响。

著录项

期刊名称 BMC Cancer
作者
Annette J Vangsted; Karen Søeby; Tobias W Klausen; Niels Abildgaard; Niels F Andersen; Peter Gimsing; Henrik Gregersen; Ulla Vogel; Thomas Werge; Henrik B Rasmussen;
展开▼
作者单位

展开▼
年(卷),期 2010(10),-1
年度 2010
页码 404
总页数 8
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Safety and efficacy of bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide maintenance (VMPT-VT) versus bortezomib-melphalan-prednisone (VMP) in untreated multiple myeloma patients with renal impairment. [J] . Morabito F, Gentile M, Mazzone C, Blood: The Journal of the American Society of Hematology . 2011,第22期

机译：硼替佐米-美法仑-泼尼松-沙利度胺联合硼替佐米-沙利度胺维持（VMPT-VT）与硼替佐米-美法仑-泼尼松（VMP）在未经治疗的多发性骨髓瘤肾功能不全患者中的安全性和有效性。
2. Effect of CYP2C19 and CYP3A4 gene polymorphisms on the efficacy of bortezomib-based regimens in patients with multiple myeloma [J] . Zhou Weiwei, An Guangyu, Jian Yuan, Oncology letters . 2015,第2期

机译：CYP2C19和CYP3A4基因多态性对多发性骨髓瘤患者基于硼替佐米治疗的疗效影响
3. Clinical efficacy of a bortezomib, cyclophosphamide, thalidomide, and dexamethasone (Vel-CTD) regimen in patients with relapsed or refractory multiple myeloma: a phase II study. [J] . Kim YK, Sohn SK, Lee JH, Annals of hematology . 2010,第5期

机译：硼替佐米，环磷酰胺，沙利度胺和地塞米松（Vel-CTD）方案在复发或难治性多发性骨髓瘤患者中的临床疗效：II期研究。
4. Association of CYP2D6 and ADRB1 Single Nucleotide Polymorphisms and Response to Beta Blocker Therapy in a Patient Sample Set with Cardiovascular Diseases from Romania [C] . Andrada Camelia Guta, Liana Gabriela Gruescu Molecular Medicine TRI-CON. . 2014

机译：CYP2D6和ADRB1单核苷酸多态性和对患者样本中β受体疗法的响应与来自罗马尼亚的心血管疾病
5. A Phase 1/2 Study of Ixazomib as a Replacement for Bortezomib or Carfilzomib for Multiple Myeloma Patients Recently Relapsed or Refractory to Their Last Combination Regimen Containing Either Bortezomib or Carfilzomib [D] . Forouzan, Eli. 2020

机译：Ixazomib的第1/2期作为替代品髓鞘或胭脂瘤患者的替代品的替代物，最近对含有Bortezomib或Carfilzomib的最后组合方案复发或难治
6. Effect of CYP2C19 and CYP3A4 gene polymorphisms on the efficacy of bortezomib-based regimens in patients with multiple myeloma [O] . WEIWEI ZHOU, GUANGYU AN, YUAN JIAN, -1

机译：CYP2C19和CYP3A4基因多态性对多发性骨髓瘤患者基于硼替佐米治疗的疗效影响
7. No influence of the polymorphisms CYP2C19 and CYP2D6 on the efficacy of cyclophosphamide, thalidomide, and bortezomib in patients with Multiple Myeloma [O] . Vangsted Annette Juul, Søeby Karen, Klausen Tobias, 2010

机译：CYP2C19和CYP2D6多态性对多发性骨髓瘤患者环磷酰胺，沙利度胺和硼替佐米的疗效无影响

No influence of the polymorphisms CYP2C19 and CYP2D6 on the efficacy of cyclophosphamide thalidomide and bortezomib in patients with Multiple Myeloma

摘要

著录项

相似文献

相关主题

期刊订阅